Evidence map›Paper›PMID 41896973›Full record

ArticleBMC chemistry2026

Compressive, hardness, and surface characterization of nanoclay-reinforced glass/epoxy laminates for structural applications.

Sakine Kiratli

Abstract read
In one paragraph

Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sakine KiratliFaculty of Engineering, Mechanical Engineering Department, Çankırı Karatekin University, Çankırı, 18100, Turkey. skiratli@karatekin.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, the effect of nanoclay reinforcement on the mechanical and surface performance of glass/epoxy laminated composites was comprehensively investigated with the aim of jointly evaluating compression behavior and surface properties, which have been addressed only to a limited extent in the literature. In particular, the study aimed to reveal the role of the nanoclay ratio in the compression strength-hardness-wettability balance and to determine the optimum reinforcement level. To this end, glass/epoxy laminates containing nanoclay at weight ratios of 0, 1, 3, and 5 wt% were produced, and the specimens were characterized using compression tests, microhardness measurements, contact angle analyses, atomic force microscopy (AFM), and scanning electron microscopy (SEM). The results obtained showed that the addition of nanoclay significantly affected both the structural integrity and surface behavior of the composites. According to experimental findings, a 3 wt% nanoclay content provided the most balanced performance, resulting in an approximate 19.4% increase in compressive strength and a 7.3% increase in hardness, while also improving surface wettability. AFM analyses confirmed a more homogeneous nanoparticle distribution and increased surface roughness at this ratio, while SEM images revealed strengthened fiber-matrix interfacial bonding and limited crack propagation. In contrast, particle agglomerations and microvoid formation were observed at a 5 wt% nanoclay content, leading to a partial decrease in mechanical performance. In conclusion, this study demonstrates that nanoclay reinforcement is a critical parameter that controls not only the mechanical strength but also the surface functionality of glass/epoxy composites, and provides a comprehensive assessment for determining the optimal nanoclay ratio for structural applications.

Indexed as

CompressiveGlass/epoxy compositesHardnessNanoclaySurface properties

Identifiers

PMID41896973
PMCPMC13032554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.